Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Gan & Lee Pharmaceuticals / Technical Analysis

<ul>
<li>We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment</li>
<li>Short-Term supports to watch on ACWI-US continue to be $132 (testing now), $130, $128, $125-$126, and $123-$123.50. All signs point to the ACWI-US uptrend continuing for the foreseeable future.</li>
<li>Upgrading China to Overweight; Europe Breaking Out; Japan Also Remains Attractive. Buys in Consumer Discretionary (primarily autos/parts), Industrials, Services, Health Care, Materials, Financials, and Real Estate</li>
</ul>


We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment
Short-Term supports to watch on ACWI-US continue to be $132 (testing now), $130, $128, $125-$126, and $123-$123.50. All signs point to the ACWI-US uptrend continuing for the foreseeable future.
Upgrading China to Overweight; Europe Breaking Out; Japan Also Remains Attractive. Buys in Consumer Discretionary (primarily autos/parts), Industrials, Services, Health Care, Materials, Financials, and Real Estate


Upgrading China to Overweight; Europe Breaking Out

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Thematic (Sector/Industry)

• RESULTS - 29th MARCH •<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/979/original/image_20691903021617048798901.png?1617048799" class="editor-image img-responsive" data-smartkarma-image-id="197979"></figure>RESULTS -  Of Monday's three results, <a href="https://www.smartkarma.com/entities/arcland-sakamoto-co-ltd" target="_blank" data-smartkarma-citation="entities:10395:1" rel="noopener">Arcland Sakamoto (9842 JP)</a> stands out but is driven by the LIXIL VIVA acquisition. The FY22 forecasts are conservative and leave ample room for an upward revision. Arcland is our preferred Home Centre holding and is back into an attractive buying zone following last year's COVID-driven spike into OverBought territory.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/985/original/image_58825059031617049684417.png?1617049685" class="editor-image img-responsive" data-smartkarma-image-id="197985"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/986/original/image_44235549241617050056401.png?1617050057" class="editor-image img-responsive" data-smartkarma-image-id="197986"></figure>• FORECASTS/REVISIONS - 29th MARCH •<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/987/original/image_83881428151617050520638.png?1617050521" class="editor-image img-responsive" data-smartkarma-image-id="197987"></figure>FORECASTS/REVISIONS - Of the 14 annual forecasts and revisions, 57% scored positively. The DETAIL Section below focuses on <a href="https://www.smartkarma.com/entities/organo-corp" target="_blank" data-smartkarma-citation="entities:1972:1" rel="noopener">Organo (6368 JP)</a> and <a href="https://www.smartkarma.com/entities/keihan-electric-railway-co" target="_blank" data-smartkarma-citation="entities:6120:1" rel="noopener">Keihan Electric Railway (9045 JP)</a>. <figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/988/original/image_80065899161617052150856.png?1617052151" class="editor-image img-responsive" data-smartkarma-image-id="197988"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/989/original/image_62815698771617052194528.png?1617052195" class="editor-image img-responsive" data-smartkarma-image-id="197989"></figure>

• RESULTS - 29th MARCH •RESULTS -  Of Monday's three results, Arcland Sakamoto (9842 JP) stands out but is driven by the LIXIL VIVA acquisition. The FY22 forecasts are conservative and leave ample room for an upward revision. Arcland is our preferred Home Centre holding and is back into an attractive buying zone following last year's COVID-driven spike into OverBought territory.• FORECASTS/REVISIONS - 29th MARCH •FORECASTS/REVISIONS - Of the 14 annual forecasts and revisions, 57% scored positively. The DETAIL Section below focuses on Organo (6368 JP) and Keihan Electric Railway (9045 JP). 

🇯🇵 JAPAN • Results & Revisions 03/​​​​​​​​29 - Arcland, Organo & Keihan

Doing bespoke work since 2002....., Custom Products Group

Patrick Hansen

Doing bespoke work since 2002.....

Custom Products Group

Custom Products was started 14 years ago at Lehman Brothers by current co-founder Patrick Hansen, CFA. After 3 years at Lehman, Patrick moved the team to Macquarie Securities where Simon Rigney (co-founder) joined. 3 years ago we took Custom Products independent. 

Our core strength can be summed up three words. 1- Customization - we have very little off the shelf products and most work is done on a one on one bespoke basis. 2- Speed - We pride ourselves in our ability to get requests back to the client very quickly. 3- Confidentiality - We do not redistribute. There is no grace period where we wait a week and then mass blast. Any request stops with that client.

We screened for names with little or no coverage that have been growing over the last couple of years and the valuations look really good. For the forecast numbers, we are using company guidance as most of the names do not have Analyst coverage. Basically we are looking for names that are not well known but are growing and valuations are cheap.Names with very low PE ratios are <a href="https://www.smartkarma.com/entities/15900" target="_blank" data-smartkarma-citation="entities:15900:1">Sanyo Special Steel Co Ltd (5481 JP)</a> with a 2x PE, <a href="https://www.smartkarma.com/entities/9957" target="_blank" data-smartkarma-citation="entities:9957:1">Toenec Corp (1946 JP)</a> with a 3x PE and <a href="https://www.smartkarma.com/entities/1972" target="_blank" data-smartkarma-citation="entities:1972:1">Organo Corp (6368 JP)</a> with a…

We screened for names with little or no coverage that have been growing over the last couple of years and the valuations look really good. For the forecast numbers, we are using company guidance as most of the names do not have Analyst coverage. Basically we are looking for names that are not well known but are growing and valuations are cheap.Names with very low PE ratios are Sanyo Special Steel Co Ltd (5481 JP) with a 2x PE, Toenec Corp (1946 JP) with a 3x PE and Organo Corp (6368 JP) with a…

Small-Cap Growth Names with Good Valuations in Japan....

Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>Organo's Q1 FY03/26 results: Orders JPY59.6bn (+13.0% YoY), revenue JPY38.1bn (+20.5% YoY), operating profit JPY7.0bn (+73.8% YoY). </li><li>Revised full-year FY03/26 forecast: Orders JPY180.0bn (+19.0% YoY), revenue JPY175.0bn (+7.2% YoY), operating profit JPY34.0bn (+9.3% YoY). </li><li>Electronics industry growth: Semiconductor projects in Taiwan, Japan, US, and increased sales of water treatment chemicals. </li></ul>

Organo's Q1 FY03/26 results: Orders JPY59.6bn (+13.0% YoY), revenue JPY38.1bn (+20.5% YoY), operating profit JPY7.0bn (+73.8% YoY). Revised full-year FY03/26 forecast: Orders JPY180.0bn (+19.0% YoY), revenue JPY175.0bn (+7.2% YoY), operating profit JPY34.0bn (+9.3% YoY). Electronics industry growth: Semiconductor projects in Taiwan, Japan, US, and increased sales of water treatment chemicals. 

Organo Corp (6368 JP): Q1 FY03/26 flash update

<ul><li>In FY03/25, Organo reported orders of JPY151.3bn, revenue of JPY163.3bn, and net income of JPY24.2bn.</li><li>Orders in the Water Treatment Engineering business totaled JPY126.3bn, with revenue reaching JPY138.1bn, driven by electronics industry demand.</li><li>For FY03/26, Organo forecasts orders of JPY180.0bn, revenue of JPY175.0bn, and net income of JPY24.2bn.</li></ul>

In FY03/25, Organo reported orders of JPY151.3bn, revenue of JPY163.3bn, and net income of JPY24.2bn.Orders in the Water Treatment Engineering business totaled JPY126.3bn, with revenue reaching JPY138.1bn, driven by electronics industry demand.For FY03/26, Organo forecasts orders of JPY180.0bn, revenue of JPY175.0bn, and net income of JPY24.2bn.

Organo Corp (6368 JP): Full-year FY03/25 flash update

Japan

ORGANO CORPORATION manufactures water treatment equipment and other related peripherals and supplies.  The Company also produces industrial chemical products such as activated carbon and charcoal, water treatment compounds, and ion exchange resins.  Organo's water treatment systems are used for ultra-pure water production in nuclear power and semiconductor manufacturing processes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Organo Corp (6368 JP)

Upgrading China to Overweight; Europe Breaking Out

Upgrading China to Overweight. Europe Breaking Out. Japan Remains Attractive. All signs point to the $ACWI uptrend continuing for the foreseeable...

Vermilion Research

🇯🇵 JAPAN • Results & Revisions 03/29 - Arcland, Organo & Keihan

Of Monday's three results, Arcland Sakamoto (9842 JP) stands out but is driven by the LIXIL VIVA acquisition. The FY22 forecasts are conservative...

Campbell Gunn

Small-Cap Growth Names with Good Valuations in Japan....

We screened for names with little or no coverage that have been growing over the last couple of years and the valuations look really good. For the...

Custom Products Group